Pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy in women with advanced ovarian cancer
Phase 1
- Conditions
- peritoneal carcinosis of ovarian origin cancerMedDRA version: 27.0Level: PTClassification code: 10057529Term: Ovarian cancer metastatic Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2024-515996-37-00
- Lead Sponsor
- Hospices Civils De Lyon
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie PIPAC's synergy with systemic chemotherapy in peritoneal carcinosis of ovarian origin?
How does PIPAC plus systemic chemotherapy compare to standard-of-care treatments for metastatic ovarian cancer in phase I trials?
Which biomarkers correlate with response to PIPAC combined with systemic chemotherapy in advanced ovarian cancer patients?
What adverse events are reported in phase I trials of PIPAC for peritoneal carcinosis, and how are they managed?
What are the current combination therapies and competitor drugs for peritoneal carcinosis of ovarian origin in phase I trials by Hospices Civils De Lyon?